LAKEFRONT BIOTHER.
Research LAKEFRONT BIOTHER. (LKFT.AS) on Bullrun: market cap EUR 1.72B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLKFT.AS
- ExchangeXAMS
- CountryBelgium
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 1.72B
- Financial periodFY2025
- RevenueEUR 1.11B
- Revenue growth303.5%
- Net incomeEUR 320.88M
- Free cash flow-EUR 271.32M
- Gross margin97.3%
Valuation Snapshot
latest market cap is EUR 1.72B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 1.11B | EUR 320.88M | -EUR 271.32M | 97.3% | 4.87 | EUR 87.87M | EUR 6.92M | EUR 3.24B |
| FY2024 | EUR 275.65M | EUR 74.08M | -EUR 402.14M | 87.4% | 1.12 | EUR 64.24M | EUR 11.72M | EUR 2.90B |
| FY2023 | EUR 239.72M | EUR 211.70M | -EUR 425.24M | 100.0% | 3.21 | EUR 166.80M | EUR 9.60M | EUR 2.80B |
| FY2022 | EUR 241.25M | -EUR 217.99M | -EUR 537.49M | 100.0% | -3.32 | EUR 508.12M | EUR 21.90M | EUR 2.53B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-10 | EUR 1.72B | n/a | n/a | n/a |
About LAKEFRONT BIOTHER.
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is LAKEFRONT BIOTHER.'s market cap?
LAKEFRONT BIOTHER.'s market capitalization is EUR 1.72B.
What does LAKEFRONT BIOTHER. do?
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.